Financing
Payment of Deferred Purchase Consideration
Pfizer Payment of Deferred Purchase Consideration decreased by 560.5% to -$284.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 20.2%, from -$356.00M to -$284.00M. Over 2 years (FY 2023 to FY 2025), Payment of Deferred Purchase Consideration shows an upward trend with a -14.8% CAGR.
Analysis
StatementCash Flow Statement
SectionFinancing
First reportedQ1 2013
Last reportedQ1 2026May 5, 2026
Metric ID:
isrg_payment_of_deferred_purchase_considerationHistorical Data
15 periods
| Q4 '21 | Q1 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $201.00M | -$501.00M | -$436.00M | -$140.00M | -$37.00M | -$18.00M | -$386.00M | -$63.00M | -$6.00M | -$14.00M | -$356.00M | -$21.00M | -$38.00M | -$43.00M | -$284.00M |
| QoQ Change | — | -349.3% | +13.0% | +67.9% | +73.6% | +51.4% | <-999% | +83.7% | +90.5% | -133.3% | <-999% | +94.1% | -81.0% | -13.2% | -560.5% |
| YoY Change | — | — | +13.0% | — | — | — | +11.5% | +55.0% | +83.8% | +22.2% | +7.8% | +66.7% | -533.3% | -207.1% | +20.2% |
Range-$501.00M – $201.00M
CAGR+10.4%
Avg YoY Growth-46.0%
Median YoY Growth+16.6%
Current Streak3 quarters decline
Payment of Deferred Purchase Consideration at Other Companies
Frequently Asked Questions
- What is Pfizer's payment of deferred purchase consideration?
- Pfizer (PFE) reported payment of deferred purchase consideration of -$284.00M in Q1 2026.
- How has Pfizer's payment of deferred purchase consideration changed year-over-year?
- Pfizer's payment of deferred purchase consideration increased by 20.2% year-over-year, from -$356.00M to -$284.00M.
- What is the long-term trend for Pfizer's payment of deferred purchase consideration?
- Over 2 years (2023 to 2025), Pfizer's payment of deferred purchase consideration has grown at a -14.8% compound annual growth rate (CAGR), from -$631.00M to -$458.00M.